Alberta Innovates Health Solutions   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Alberta Canada (2016)

Organization Overview

First Clinical Trial
2016
NCT01967329
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Alberta Innovates Health Solutions

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 2)

Choroideremia (Phase 2)

Death (Phase 2)

Death, Sudden, Cardiac (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Hypercholesterolemia (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Neoplasm Metastasis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 20